244 related articles for article (PubMed ID: 12630848)
1. Biochemical modulation of Cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance.
Fuertes MA; Alonso C; Pérez JM
Chem Rev; 2003 Mar; 103(3):645-62. PubMed ID: 12630848
[No Abstract] [Full Text] [Related]
2. DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine, or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines.
Kasparkova J; Marini V; Najajreh Y; Gibson D; Brabec V
Biochemistry; 2003 May; 42(20):6321-32. PubMed ID: 12755637
[TBL] [Abstract][Full Text] [Related]
3. Biochemical studies of the thermal effects on DNA modifications by the antitumor cisplatin and their repair.
Halamikova A; Vrana O; Kasparkova J; Brabec V
Chembiochem; 2007 Nov; 8(16):2008-15. PubMed ID: 17868156
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin.
Reed E
Cancer Chemother Biol Response Modif; 1999; 18():144-51. PubMed ID: 10800481
[No Abstract] [Full Text] [Related]
5. Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology.
Timerbaev AR; Hartinger CG; Aleksenko SS; Keppler BK
Chem Rev; 2006 Jun; 106(6):2224-48. PubMed ID: 16771448
[No Abstract] [Full Text] [Related]
6. Superior antitumor efficiency of cisplatin-loaded nanoparticles by intratumoral delivery with decreased tumor metabolism rate.
Li X; Li R; Qian X; Ding Y; Tu Y; Guo R; Hu Y; Jiang X; Guo W; Liu B
Eur J Pharm Biopharm; 2008 Nov; 70(3):726-34. PubMed ID: 18634874
[TBL] [Abstract][Full Text] [Related]
7. Loss of amine from platinum(II) complexes: implications for cisplatin inactivation, storage, and resistance.
Lau JK; Deubel DV
Chemistry; 2005 Apr; 11(9):2849-55. PubMed ID: 15744707
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin: mode of cytotoxic action and molecular basis of resistance.
Siddik ZH
Oncogene; 2003 Oct; 22(47):7265-79. PubMed ID: 14576837
[TBL] [Abstract][Full Text] [Related]
10. The molecular perspective: cisplatin.
Goodsell DS
Oncologist; 2006 Mar; 11(3):316-7. PubMed ID: 16549816
[No Abstract] [Full Text] [Related]
11. Effects of a piperidine ligand on DNA modification by antitumor cisplatin analogues.
Kasparkova J; Novakova O; Najajreh Y; Gibson D; Perez JM; Brabec V
Chem Res Toxicol; 2003 Nov; 16(11):1424-32. PubMed ID: 14615968
[TBL] [Abstract][Full Text] [Related]
12. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
Brabec V; Nováková O
Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363
[TBL] [Abstract][Full Text] [Related]
13. DNA interactions of new antitumor platinum complexes with trans geometry activated by a 2-metylbutylamine or sec-butylamine ligand.
Prokop R; Kasparkova J; Novakova O; Marini V; Pizarro AM; Navarro-Ranninger C; Brabec V
Biochem Pharmacol; 2004 Mar; 67(6):1097-109. PubMed ID: 15006546
[TBL] [Abstract][Full Text] [Related]
14. Activity of lipoplatin in tumor and in normal cells in vitro.
Arienti C; Tesei A; Ravaioli A; Ratta M; Carloni S; Mangianti S; Ulivi P; Nicoletti S; Amadori D; Zoli W
Anticancer Drugs; 2008 Nov; 19(10):983-90. PubMed ID: 18827563
[TBL] [Abstract][Full Text] [Related]
15. Three new asymmetric trans-amine(azole)dichloridoplatinum complexes that overcome cisplatin resistance and their reactions with 5'-GMP.
Pantoja E; Gallipoli A; van Zutphen S; Komeda S; Reddy D; Jaganyi D; Lutz M; Tooke DM; Spek AL; Navarro-Ranninger C; Reedijk J
J Inorg Biochem; 2006 Dec; 100(12):1955-64. PubMed ID: 17083978
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin and platinum drugs at the molecular level. (Review).
Boulikas T; Vougiouka M
Oncol Rep; 2003; 10(6):1663-82. PubMed ID: 14534679
[TBL] [Abstract][Full Text] [Related]
17. Bypass of DNA lesions generated during anticancer treatment with cisplatin by DNA polymerase eta.
Alt A; Lammens K; Chiocchini C; Lammens A; Pieck JC; Kuch D; Hopfner KP; Carell T
Science; 2007 Nov; 318(5852):967-70. PubMed ID: 17991862
[TBL] [Abstract][Full Text] [Related]
18. Potential role of transforming growth factor beta1 in drug resistance of tumor cells.
Stoika R; Yakymovych M; Souchelnytskyi S; Yakymovych I
Acta Biochim Pol; 2003; 50(2):497-508. PubMed ID: 12833174
[TBL] [Abstract][Full Text] [Related]
19. Determination of the DNA-binding characteristics of ethidium bromide, proflavine, and cisplatin by flow injection analysis: usefulness in studies on antitumor drugs.
Alonso A; Almendral MJ; Curto Y; Criado JJ; Rodríguez E; Manzano JL
Anal Biochem; 2006 Aug; 355(2):157-64. PubMed ID: 16842734
[TBL] [Abstract][Full Text] [Related]
20. In vitro biochemical and pharmacological evaluation of a novel cytotoxic dinuclear platinum(II) complex with 3-amino-5-methyl-5-phenylhydantoin.
Momekov GTs; Ugrinova I; Pasheva EA; Bakalova AG; Varbanov HP; Ferdinandov DV; Ivanov DS; Konstantinov SM
Ann N Y Acad Sci; 2009 Aug; 1171():649-58. PubMed ID: 19723116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
